The case for beta-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality

Arch Surg. 2001 Mar;136(3):286-90. doi: 10.1001/archsurg.136.3.286.

Abstract

Perioperative morbidity and mortality are frequently cardiac in origin. Many studies have prospectively attempted to define risk factors for cardiac ischemic events. Although we can now identify high-risk patients, optimal cardioprotective management strategies remain unclear. Treatment with beta-adrenergic antagonists decreases myocardial oxygen consumption and is generally well tolerated. This article reviews the physiologic and clinical basis for using these agents as prophylaxis against cardiovascular events in high-risk surgical patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Adrenergic beta-Antagonists / adverse effects
  • Animals
  • Arrhythmias, Cardiac / mortality
  • Arrhythmias, Cardiac / prevention & control*
  • Heart Failure / mortality
  • Heart Failure / prevention & control*
  • Humans
  • Myocardial Infarction / mortality
  • Myocardial Infarction / prevention & control*
  • Myocardium / metabolism
  • Oxygen Consumption / drug effects
  • Postoperative Complications / mortality
  • Postoperative Complications / prevention & control*
  • Premedication
  • Randomized Controlled Trials as Topic
  • Survival Rate

Substances

  • Adrenergic beta-Antagonists